0
Critical Care: Critical Care: ARDS/ALI |

Eriodictyol, a Plant Flavonoid, Attenuates LPS-Induced Acute Lung Injury Through Its Antioxidative and Antiinflammatory Activity FREE TO VIEW

Hongjuan Guo
Author and Funding Information

Beijing Anzhen Hospital, Beijing, China


Copyright 2016, American College of Chest Physicians. All Rights Reserved.


Chest. 2016;149(4_S):A156. doi:10.1016/j.chest.2016.02.162
Text Size: A A A
Published online

SESSION TITLE: Critical Care: ARDS/ALI

SESSION TYPE: Original Investigation Poster

PRESENTED ON: Saturday, April 16, 2016 at 11:45 AM - 12:45 PM

PURPOSE: Acute lung injury (ALI) is characterized by excessive inflammatory responses and oxidative injury in lung tissue and the anti-inflammatory or anti-oxidative agent is proposed to be a therapeutic drugs for ALI. Eriodictyol has been reported to have anti-oxidative and anti-inflammatory activity in vitro assay. In this study, we investigated the effect of eriodictyol on the LPS-induced acute lung injury in mice model.

METHODS: Before ALI induction, mice were orally pretreated with eriodictyol once (30mg/kg) 2 days and then the mice were divided into four groups: PBS treated health control group (Ctr group), LPS-induced ALI group (LPS group), vehicle treated ALI group (LPS+Vehicel group), and eriodictyol treated ALI group (LPS+Eriodictyol group).

RESULTS: Our data demonstrated that eriodictyol pretreatment attenuated LPS-induced ALI through its anti-oxidative activity and anti-inflammatory activity. Eriodictyol could activate the Nrf2 pathway in ALI mouse model to impair the oxidative injury and inhibit the inflammatory cytokines expression in macrophages.

CONCLUSIONS: Taken together, our results demonstrated that eriodictyol could alleminate LPS-induced lung injury in mice through regulating Nrf2 pathway and inhibiting inflammatory cytokines expression in macrophages, suggesting that eriodictyol might be used as a potential drug for the treatment of LPS-induced lung injury.

CLINICAL IMPLICATIONS: Eriodictyol might be used as a potential drug for the treatment of LPS-induced lung injury.

DISCLOSURE: Hongjuan Guo: Consultant fee, speaker bureau, advisory committee, etc.: The national natural science foundation

No Product/Research Disclosure Information


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543